

Hermine Agis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2933706/publications.pdf>

Version: 2024-02-01

55
papers

675
citations

623734

14
h-index

610901

24
g-index

56
all docs

56
docs citations

56
times ranked

1316
citing authors

#	ARTICLE	IF	CITATIONS
1	Successful treatment of acquired von Willebrand syndrome associated with monoclonal gammopathy. Wiener Klinische Wochenschrift, 2022, 134, 478-482.	1.9	6
2	Corneal Toxicity Associated With Belantamab Mafodotin Is Not Restricted to the Epithelium: Neuropathy Studied With Confocal Microscopy. American Journal of Ophthalmology, 2022, 242, 116-124.	3.3	7
3	Reverse Remodeling Following Valve Replacement in Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2022, 15, .	2.6	12
4	Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis. Clinical Research in Cardiology, 2021, 110, 532-543.	3.3	21
5	CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection. Transplantation, 2021, 105, 451-457.	1.0	57
6	Short tutorial. Treatment options in light chain amyloidosis and monoclonal gammopathy of renal significance. Memo - Magazine of European Medical Oncology, 2021, 14, 80-88.	0.5	0
7	Immunoglobulin light chain amyloidosis. Memo - Magazine of European Medical Oncology, 2021, 14, 103-110.	0.5	1
8	Paraprotein-associated diseases: a complex relationship between monoclonal gammopathy of unknown significance and severe organ damage. Memo - Magazine of European Medical Oncology, 2021, 14, 9-10.	0.5	0
9	Hemophagocytic lymphohistiocytosis in COVID-19. Medicine (United States), 2021, 100, e25170.	1.0	17
10	The Agony of Choice – Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. Cancers, 2021, 13, 4701.	3.7	6
11	Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM. Cancers, 2021, 13, 5886.	3.7	4
12	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. Blood, 2021, 138, 153-153.	1.4	6
13	Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study). Blood, 2021, 138, 1669-1669.	1.4	0
14	Convolutional Neural Networks for Fully Automated Diagnosis of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging. Journal of Personalized Medicine, 2021, 11, 1268.	2.5	5
15	Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response. Annals of Hematology, 2020, 99, 2599-2609.	1.8	4
16	Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wiener Klinische Wochenschrift, 2020, 132, 742-761.	1.9	31
17	Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots. Journal of Clinical Medicine, 2020, 9, 2234.	2.4	10
18	Machine Learning Enables Prediction of Cardiac Amyloidosis by Routine Laboratory Parameters: A Proof-of-Concept Study. Journal of Clinical Medicine, 2020, 9, 1334.	2.4	13

#	ARTICLE	IF	CITATIONS
19	Light chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. <i>European Journal of Heart Failure</i> , 2020, 22, 1852-1862.	7.1	82
20	Hemodynamic Profiles and Their Prognostic Relevance in Cardiac Amyloidosis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1093.	2.4	6
21	Renal Expression of Light Chain Binding Proteins. <i>Frontiers in Medicine</i> , 2020, 7, 609582.	2.6	2
22	First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. <i>Blood</i> , 2020, 136, 50-51.	1.4	12
23	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. <i>ESMO Open</i> , 2020, 5, e000880.	4.5	4
24	Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed by Carfilzomib Maintenance or Control (AGMT MM 02 Study). <i>Blood</i> , 2020, 136, 29-30.	1.4	0
25	Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial). <i>Blood</i> , 2020, 136, 27-29.	1.4	0
26	Riociguat for the treatment of transthyretin cardiac amyloidosis: data from a named patient use program in Austria. <i>Pulmonary Circulation</i> , 2019, 9, 1-9.	1.7	1
27	Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using ¹⁸ F-FDG-PET/CT and ¹⁸ F-NaF-PET/CT. <i>Anticancer Research</i> , 2019, 39, 1943-1952.	1.1	3
28	Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia*. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 936-953.	3.8	30
29	Mechanisms of heart failure in transthyretin vs. light chain amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 512-524.	1.2	26
30	Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis. <i>Journal of Intensive Care Medicine</i> , 2019, 34, 723-731.	2.8	86
31	Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2) Tj ETQq1 1 0.784314 rgBT /Overl	1.4	4
32	Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02). <i>Blood</i> , 2019, 134, 696-696.	1.4	4
32	Structural analysis of urinary light chains and proteomic analysis of hyaline tubular casts in light chain associated kidney disorders. <i>PeerJ</i> , 2019, 7, e7819.	2.0	2
33	Firstline Daratumumab Shows High Hematologic and Organ Response Rates in Advanced Cardiac AL Amyloidosis - a Retrospective Case Series. <i>Blood</i> , 2019, 134, 3123-3123.	1.4	1
34	N-terminal B-type natriuretic peptide (NT-proBNP) is associated with disease severity in multiple myeloma. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12905.	3.4	8
35	Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. <i>BMC Cancer</i> , 2018, 18, 1008.	2.6	27
36	SP295LONGITUDINAL EVALUATION OF RENAL FUNCTION IN MULTIPLE MYELOMA. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i443-i443.	0.7	0

#	ARTICLE	IF	CITATIONS
37	Impaired efferocytosis by monocytes in multiple myeloma. <i>Oncology Letters</i> , 2018, 16, 409-416.	1.8	9
38	Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of Real World Data from an Ongoing, National, Multi-Center, Non-Interventional Study. <i>Blood</i> , 2018, 132, 2018-2018.	1.4	1
39	Association Between Osteogenesis and Inflammation During the Progression of Calcified Plaque Evaluated by ¹⁸ F-Fluoride and ¹⁸ F-FDG. <i>Journal of Nuclear Medicine</i> , 2017, 58, 968-974.	5.0	40
40	Cardiac extracellular matrix is associated with adverse outcome in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 502-511.	7.1	17
41	News in AL Amyloidosis ASH 2016. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 66-71.	0.5	4
42	Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. <i>Journal of Clinical Apheresis</i> , 2017, 32, 224-234.	1.3	28
43	Amyloid in the heart: an under-recognized threat at the interface of cardiology, haematology, and pathology. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 978-980.	1.2	10
44	Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1831-1838.	1.3	23
45	Does Renal Failure Affect Outcome after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma?. <i>Blood</i> , 2016, 128, 4642-4642.	1.4	2
46	Haematopoietic stem cell transplantation for treatment of primary ^{sc} CNS lymphoma: single-centre experience and literature review. <i>European Journal of Haematology</i> , 2015, 95, 75-82.	2.2	10
47	BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.. <i>Blood</i> , 2010, 116, 3382-3382.	1.4	0
48	Revealing Six Phases of CML Stem Cell Development to Explain Clinical Phenomena Seen in TKI-Treated Patients.. <i>Blood</i> , 2009, 114, 4263-4263.	1.4	0
49	Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.. <i>Blood</i> , 2007, 110, 4556-4556.	1.4	0
50	Identification of Basogranulin (BB1) as a Novel Immunohistochemical Marker of Basophils in Normal Bone Marrow and Patients With Myeloproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2006, 125, 273-281.	0.7	16
51	Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis. <i>Leukemia Research</i> , 2005, 29, 1227-1232.	0.8	12
52	Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.. <i>Blood</i> , 2005, 106, 3516-3516.	1.4	1
53	Detection of Trisomy 8 in Donor-Derived Ph ⁺ Cells in a Patient with Ph+Chronic Myeloid Leukemia Successfully Treated with Imatinib (STI571) in Relapse after Allogeneic Transplantation. <i>Leukemia and Lymphoma</i> , 2004, 45, 1453-1458.	1.3	7
54	Histidine Decarboxylase (HDC) as Novel Marker of Immature Neoplastic Mast Cells in Systemic Mastocytosis.. <i>Blood</i> , 2004, 104, 4755-4755.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Enumeration and Immunologic Characterization of Basophils in Normal Bone Marrow and Patients with Myeloproliferative Disorders.. Blood, 2004, 104, 4754-4754.	1.4	0